Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23306918 | 0.89 | ACE (0.50) | ESR1ESR2FOLH1ACEMME | |
| SCHEMBL12894465 | 0.88 | ACE (0.52) | ESR1ESR2FOLH1SLC7A5TAAR1 | |
| SCHEMBL12869808 | 0.86 | FOLH1 (0.61) | FOLH1SLC7A5ACEMMECPA1 | |
| SCHEMBL5738141 | 0.86 | FOLH1 (0.61) | FOLH1SLC7A5ACEMMECPA1 | |
| SCHEMBL13356097 | 0.85 | ACE (0.49) | ESR1ESR2FOLH1SLC7A5TAAR1 | |
| SCHEMBL684443 | 0.85 | ACACB (0.49) | SLC6A2GAASMN1; SMN2 | |
| SCHEMBL13323478 | 0.85 | ACACB (0.49) | SLC6A2GAASMN1; SMN2 | |
| SCHEMBL7601953 | 0.85 | FOLH1 (0.49) | ESR1ESR2FOLH1SLC7A5TAAR1 | |
| SCHEMBL23306932 | 0.85 | NPC1 (0.43) | ESR1ESR2MME | |
| SCHEMBL27250348 | 0.85 | FOLH1 (0.49) | ESR1ESR2FOLH1SLC7A5TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149845-A1 | METHODS FOR CELL SURFACE REMODELING | NANTES UNIVERSITÉ (FR) | 2024-07-18 | — | — | WO | disclosed |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20210121585-A1 | PSMA targeted radiotherapy medicine and preparation method thereof | LI MING HSIN (TW) | 2021-04-29 | — | — | US | disclosed |
| US-20200361944-A1 | FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES | ZEALAND PHARMA A/S (DK) | 2020-11-19 | — | — | US | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
| US-20120021029-A1 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LIPOTEC, S.A. (ES) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021029-A1 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | NGLY1, MC1R, NPR3 | ESR1 4227/4885ESR2 2250/4885FOLH1 695/4885 |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | ESR1 4240/4885ESR2 4222/4885FOLH1 1198/4885 |
| US-20210121585-A1 | PSMA targeted radiotherapy medicine and preparation method thereof | FOLH1, KLK3, PSMA1 | ESR1 673/4885ESR2 1107/4885FOLH1 1/4885 |
| US-20200361944-A1 | FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES | VIP, NPPA, NGLY1 | ESR1 4524/4885ESR2 2631/4885FOLH1 109/4885 |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | ESR1 4240/4885ESR2 4222/4885FOLH1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.